Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Leo Eickhoff

Gastroenterology Redding, CA Medical Doctor

NPI 1871609966 CMS profile 986419

1825 Sonoma St, Redding, CA 96001

Open in the dashboard

General payments

$4,473

223 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Leo Eickhoff of Redding, CA is reported in the CMS Open Payments database as having received $4,473 across 223 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $540 26
2024 General $771 39
2023 General $555 27
2022 General $776 41
2021 General $833 34
2020 General $566 29
2019 General $432 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Leo Eickhoff
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Leo Eickhoff were reported at $540. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Leo Eickhoff Gastroenterology median Middle half National median
2019 $432 $417 $126–$1,100 $163
2020 $566 $224 $74–$624 $114
2021 $833 $352 $106–$1,054 $132
2022 $776 $448 $129–$1,270 $149
2023 $555 $533 $150–$1,390 $160
2024 $771 $605 $160–$1,606 $164
2025 $540 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,151 110 payments
  2. Janssen Biotech, Inc. $477 21 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $440 22 payments
  4. Celgene Corporation $267 15 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $186 5 payments
  6. Pfizer Inc. $139 7 payments
  7. Lilly USA, LLC $138 5 payments
  8. QOL Medical, LLC $107 12 payments
  9. Braintree Laboratories, Inc. $97 5 payments
  10. Intercept Pharmaceuticals, Inc. $77 4 payments
  11. Other $394 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,373 222 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $828 37 payments
  2. CREON $649 39 payments
  3. HUMIRA $446 17 payments
  4. STELARA $442 19 payments
  5. ENTYVIO $303 14 payments
  6. SKYRIZI Immunology $294 16 payments
  7. ZEPOSIA $267 15 payments
  8. SKYRIZI Immunology $258 13 payments
  9. LINZESS $246 17 payments
  10. XIFAXAN $186 5 payments
  11. Other $1,311 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

894

Median for Gastroenterology: 569

Drug cost

$21,049

Median for Gastroenterology: $104,976

Branded share of claims

59.1%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mesalamine Generic 13 $4,309
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 170 $3,864
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 17 $2,716
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 157 $2,128
Pantoprazole Sodium Generic 202 $2,122
Peg-3350 And Electrolytes Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 139 $2,103
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 32 $2,063
Omeprazole Generic 106 $990
Famotidine Generic 32 $348
Gavilyte-N Sodium Chloride/Nahco3/Kcl/Peg Brand 13 $236

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$129,415

Medicare's payments for the services billed

Medicare patients

717

Average age 72

Services billed

1,278

410 women, 307 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 44%
Diabetes 33%
Ischemic heart disease 23%
Depression 23%
Chronic kidney disease 21%
COPD 19%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RINVOQ
  • AbbVie, Inc. $180
$180 — —
SKYRIZI
  • AbbVie, Inc. $146
$146 — —
OMVOH
  • Lilly USA, LLC $84
$84 — —
CREON
  • AbbVie, Inc. $72
$72 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

223 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record